CONCLUSIONS: We conducted a systematic review of the literature concerning effect of treatment for non-atopic CNPG. Due to few randomized controlled trials (RCTs) and case series, the literature was unfortunately too sparse to conduct a meta-analysis of the results. Instead, we thoroughly report important data from the three existing RCTs and 6 case studies with more than 15 patients. Evaluated therapies include nemolizumab, aprepitant, topical therapy with hydrocortisone and pimecrolimus, thalidomide, UVA phototherapy, pregabalin, and naltrexone. Included RCTs and case studies all had a heterogeneous methodology making direct comparison almost impossible.
CONCLUSIONS: There is sparse evidence for the currently used therapies for non-atopic CNPG. Several RCTs on new therapies are running or in the pipeline, hopefully providing new, effective, and targeted treatment possibilities for CNPG patients both with and without an atopic predisposition.
结论:我们对有关非特应性CNPG治疗效果的文献进行了系统综述。由于随机对照试验(RCT)和病例系列很少,不幸的是,文献太稀少,无法对结果进行荟萃分析.相反,我们彻底报道了3项现有RCT和6项超过15例患者的病例研究的重要数据.评估的疗法包括奈莫珠单抗,阿瑞匹坦,局部用氢化可的松和吡美莫司治疗,沙利度胺,UVA光疗,普瑞巴林,还有纳曲酮.纳入的RCT和案例研究都有不同的方法,使得直接比较几乎是不可能的。
结论:目前用于非特应性CNPG治疗的证据很少。一些关于新疗法的随机对照试验正在运行或正在进行中,希望提供新的,有效,以及有和没有特应性易感性的CNPG患者的针对性治疗可能性。